HealthBeacon PLC HealthBeacon - HBCN - Included in Evernorth's Digital Health Formulary

Healthbeacon

15/09/2022 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220915:nRSO5918Za&default-theme=true

RNS Number : 5918Z  HealthBeacon PLC  15 September 2022

HealthBeacon's Injection Care Management System added to Evernorth's Digital
Health Formulary

Dublin, 15 September 2022: HealthBeacon plc ("HealthBeacon" or the "Company"),
the leading digital therapeutics company for managing injectable medications
for patients in the home, is pleased to announce its evidence-based Injection
Care Management System ("ICMS") has been included on Evernorth's Digital
Health Formulary, which connects employers, insurers, and patients with
innovative, affordable, and evidence-based care that meet their broader health
care needs. The ICMS will help improve care and adherence therapy for
thousands of patients in the U.S. who depend on injectable medications to
manage inflammatory conditions.

 

Approximately 50% of patients fail to adhere to their therapy when long-term
medication is prescribed (WHO).  Adherence and persistence are key factors
associated with the effectiveness of all pharmacological therapies as well as
being particularly critical for medications prescribed for chronic conditions.

 

Jim Joyce, CEO, and co-founder of HealthBeacon, said: "Inclusion on the
Evernorth Digital Health Formulary is a significant and exciting milestone for
HealthBeacon, unlocking greater access to our injection care management system
for the millions of patients in the U.S. that self-administer subcutaneous
injections at home. Collaborating with Evernorth not only supports
HealthBeacon's ambition to make our product globally accessible, but it is
also an important validation of the clinical effectiveness of our technology.
This development is further evidence that our ambition to be a global leader
in adherence devices is being realised."

 

HealthBeacon's ICMS has improved medication adherence for patients on
injection therapy by up to 26%. It includes a Federal Drug Administration
(FDA)-cleared Smart Sharps Bin device technology, Companion Medication
Adherence mobile app, as well as a sustainable mail-back waste management
solution.

 

Evernorth's Digital Health Formulary is an industry-first platform of credible
health apps created in 2019 to make it easier for patients, employers, and
health plans to navigate the crowded digital health landscape. Solutions on
the Evernorth Digital Health Formulary are reviewed by physicians,
pharmacists, and user experience experts, and are only added if they meet
quality standards for clinical effectiveness, security and privacy
requirements, value and affordability, and user experience.

 

 Enquiries:
 HealthBeacon:                                    Investor.Relations@HealthBeacon.com

                                                (mailto:Investor.Relations@HealthBeacon.com)
 Laurence Flavin

 Goodbody (Euronext Listing Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Cathal Barry                                     +353 (0) 87 227 9281
 Paul Clifford                                    +353 (0) 87 327 2161

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems. The
Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Smart
Pills(tm) which integrate with its existing technology. The Company operates
across Europe, North America and the United Kingdom and employs more than 70
people and has obtained more than 30 design and utility patents. The Company's
mission is to become the world's leading digital therapeutics platform for
patients managing medications in the home.

 

Ends

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEFIFSTARIELIF